Pioneering Therapy | Third Harmonic Bio's THB335, an oral wild-type KIT inhibitor, shows promise in treating mast-cell driven diseases, addressing an untapped area in inflammation and immunology |
Market Potential | Analysts estimate peak US sales for chronic spontaneous urticaria at $2.7 billion, highlighting the significant commercial opportunity for THB335 |
Explore Clinical Progress | THB335's accelerated development timeline, with Phase 1 data expected in Q1 2025, positions Third Harmonic Bio for rapid advancement in the competitive biotech landscape |
Financial Strength | With $255.3 million in cash and a current ratio of 42.5, Third Harmonic Bio is well-positioned to fund operations through 2026, supporting its ambitious clinical programs |
Metrics to compare | THRD | Peers Peers - average of corresponding metrics from companies closely matching THRD: | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipTHRDPeersSector |
|---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | −0.4x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.0x | 2.6x | |
Price / LTM Sales | 0.0x | 0.0x | 3.0x | |
Upside (Analyst Target) | 0.0% | 0.0% | 55.8% | |
Fair Value Upside | Unlock | 0.0% | 8.3% | Unlock |